AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Health Catalyst (HCAT) shares fell 7.3% after Q3 earnings showed weak financial outlook, with flat sales compared to last year. The company's revenue guidance for Q4 and 2026 was below analysts' estimates, prompting analysts to lower their price target and revise earnings estimates downward. Despite the stock market overreaction, big price drops can present opportunities to buy high-quality stocks.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet